Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0024

View: 7291 Download: 1,270 Web of Science: 5 Crossref: 6

Acute kidney injury in liver cirrhosis: new definition and application

Florence Wong

Clin Mol Hepatol. 2016;22(4):415-422. Published online December 14, 2016

DOI: https://doi.org/10.3350/cmh.2016.0056

View: 14443 Download: 760 Web of Science: 55 Crossref: 59

Original Article

Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal

Yun Jung Choi, Jeong Han Kim, Ja Kyung Koo, Cho I Lee, Ji Young Lee, Jae Hoon Yang, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee

Clin Mol Hepatol. 2014;20(2):185-191. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.185

View: 9685 Download: 117 Web of Science: 32 Crossref: 27

Case Report

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome

Hae Rim Kim, Young Sun Lee, Hyung Joon Yim, Hyun Joo Lee, Ja Young Ryu, Hyun Jung Lee, Eileen L. Yoon, Sun Jae Lee, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Rok Sun Choung, Sang Woo Lee, Jai Hyun Choi

Clin Mol Hepatol. 2013;19(4):417-420. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.417

View: 8299 Download: 115 Crossref: 7

A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease

Heon Ju Lee, Myung Jin Oh

Clin Mol Hepatol. 2013;19(2):179-184. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.179

View: 7425 Download: 79 Crossref: 10

7

The Korean Journal of Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome

Oh Sang Kwon, M.D.

Clin Mol Hepatol. 2010;16(1):100-102. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.100

View: 3846 Download: 30

1 |

Viewed By 6000	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5522	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5305	MAFLD: How is it different from NAFLD?
Viewed By 5278	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4860	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 146	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 109	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search